dc.contributor.author | Caly, Leon et al. | |
dc.date.accessioned | 2020-04-09T05:33:34Z | |
dc.date.available | 2020-04-09T05:33:34Z | |
dc.date.issued | 2020-04-03 | |
dc.identifier.uri | https://doi.org/10.1016/j.antiviral.2020.104787 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/988 | |
dc.description.abstract | Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect ∼5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans. | en_US |
dc.language | English | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | Infectious Diseases | en_US |
dc.subject | Ivermectin | en_US |
dc.subject | Parasitic Diseases | en_US |
dc.title | The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro | en_US |
eihealth.country | Others | en_US |
eihealth.category | Candidate therapeutics RD | en_US |
eihealth.type | Other publications | en_US |
eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
dc.relation.ispartofjournal | Antiviral Research | en_US |